The chapter explores the potential paradigm shift in psychiatry through the upcoming wave of research in psychedelics and MDMA. It discusses the interest in creating novel derivatives of psychedelics for commercial advantage and Professor David Nutt's curiosity in understanding the therapeutic differences of MDMA from drugs like methamphetamine.
Major trials are bringing us a step closer to seeing psychedelic substances used in therapy practice for PTSD, anxiety and depression. On this episode of All in the Mind, we take a look at where the research is currently at.